Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06045247
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Conditions
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06023641
- Locations
- 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸Sanford University, Palo Alto, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 20
- Registration Number
- NCT05990985
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 180
- Registration Number
- NCT05959720
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Fate Therapeutics
- Registration Number
- NCT05934097
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 332
- Registration Number
- NCT05899621
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT05887726
- Locations
- 🇨🇳
Xing Xiaojing, Shenyang, Liaoning, China
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 284
- Registration Number
- NCT05848765
- Locations
- 🇬🇧
Cardiff and vale University LHB, Cardiff, United Kingdom
🇬🇧Belfast Health & Social Care Trust, Belfast, United Kingdom
🇬🇧NHS Grampian, Aberdeen, United Kingdom
CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients.
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Moi University
- Target Recruit Count
- 100
- Registration Number
- NCT05844670
- Locations
- 🇰🇪
Moi Teaching and Referral Hospital, Eldoret, Rift Valley, Kenya
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Target Recruit Count
- 200
- Registration Number
- NCT05678933
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.